T-Select HLA-A*24:02 survivin-2B Tetramer-AYACNTSTL-APC

MBL

Catalog No: MBL-TS-M025-2

Browse all MBL products from our MBL products homepage.

The α3 mutation significantly reduces the binding of MHC tetramer to human CD8. To minimizes the aberrant effect of some CD8 antibodies; clone SFCI21Thy2D3 (also known as “T8”) is recommended.

Product Specifications

• Application: FC
• Reactivity: Human
• Conjugation: APC
• Peptide Sequence: AYACNTSTL
• Class: Class I
• Sequence Location: 80-88
• MHC Allele: A*24:02

Citations for T-Select HLA-A*24:02 survivin-2B Tetramer-AYACNTSTL-APC – 2 Found

Kameshima, Hidekazu; Tsuruma, Tetsuhiro; Torigoe, Toshihiko; Takahashi, Akari; Hirohashi, Yoshihiko; Tamura, Yasuaki; Tsukahara, Tomohide; Ichimiya, Shingo; Kanaseki, Takayuki; Iwayama, Yuji; Sato, Noriyuki; Hirata, Koichi. Immunogenic enhancement and clinical effect by type-I interferon of anti-apoptotic protein, survivin-derived peptide vaccine, in advanced colorectal cancer patients. Cancer Science. 2011;102(6):1181-7. 

Miyazaki, Akihiro; Kobayashi, Junichi; Torigoe, Toshihiko; Hirohashi, Yoshihiko; Yamamoto, Takashi; Yamaguchi, Akira; Asanuma, Hiroko; Takahashi, Akari; Michifuri, Yoshitaka; Nakamori, Kenji; Nagai, Itaru; Sato, Noriyuki; Hiratsuka, Hiroyoshi. Phase I clinical trial of survivin-derived peptide vaccine therapy for patients with advanced or recurrent oral cancer. Cancer Science. 2011;102(2):324-9.